Skip to content

Cognitive & Neuroprotective

Cerebrolysin

Porcine brain–derived neurotrophic peptide mixture approved abroad for stroke, dementia and TBI; modest, mixed human trial results.

InvestigationalEvidence level 4 of 5: Human RCTs or approved abroadAlso: FPF-1070, Porcine brain peptide preparation

Overview

Cerebrolysin is a standardized preparation of low-molecular-weight peptides and free amino acids obtained from purified pig brain protein. It is designed to mimic the activity of the brain's own neurotrophic factors such as BDNF, GDNF and NGF, supporting neuron survival, synaptic plasticity and repair after injury. It is given as a course of intramuscular or intravenous injections rather than as a daily ongoing therapy. Although widely prescribed in Europe, Russia and Asia for ischemic stroke, vascular and Alzheimer's dementia, and traumatic brain injury, it has never been approved in the United States. Trial results are mixed: some studies show improved early functional recovery, while pooled analyses show no mortality benefit. Its porcine origin means allergy screening matters.

Classification
Porcine brain–derived low-molecular-weight peptide and amino-acid preparation
Route
Intramuscular or intravenous infusion
Half-life
Not well defined (heterogeneous peptide mixture); clinical effects can persist weeks to months after a course

Mechanism of action

Primary targetMultimodal neurotrophic-factor–like signaling (BDNF/GDNF/NGF pathways)
  1. IM or IV coursePeptide mixture delivered over a 10–20 day course of injections or infusions.
  2. Neurotrophic-mimetic signalingLow-molecular-weight peptides engage pathways normally activated by BDNF, GDNF and NGF.
  3. Reduced apoptosis and excitotoxicityCalpain inhibition and anti-apoptotic signaling protect neurons stressed by ischemia or injury.
  4. Lower neuroinflammationMicroglial activation and inflammatory cytokines decrease in animal models of stroke and dementia.
  5. Synaptic and dendritic repairNeurogenesis and synaptic density increase, supporting network plasticity during recovery.
Downstream effects
  • Post-stroke functional recovery
  • Cognitive support in dementia
  • Neuroprotection after TBI

Researched for

  • Acute ischemic stroke recovery
  • Vascular dementia
  • Alzheimer's disease
  • Traumatic brain injury
  • Pediatric neurodevelopmental disorders

Research notes

  • The CARS trials (2016) suggested improved early motor recovery when started within 72 hours of stroke, but larger trials such as CASTA showed no overall benefit.
  • Cochrane 2023 (7 RCTs, 1,773 participants): probably no effect on all-cause death in acute ischemic stroke; possible increase in non-fatal serious adverse events.
  • Meta-analyses in Alzheimer's and vascular dementia report small improvements in global function and cognition over 4–6 months; trial quality is moderate.
  • Use for cognitive enhancement in healthy adults has not been studied in controlled trials.

Reported side effects

  • Injection-site pain or stinging (IM)
  • Hypersensitivity reactions (porcine origin)
  • Dizziness or headache
  • Agitation or restlessness
  • Sweating or flushing during infusion

Contraindications & cautions

  • Allergy to porcine proteins or any component
  • Severe renal impairment
  • Status epilepticus or uncontrolled seizure disorder
  • Pregnancy and breastfeeding

Lab monitoring

  • CBC, CMP
  • Vitamin B12, folate
  • Thyroid panel (TSH, free T4)
  • Vitamin D (25-OH)
  • Fasting glucose, HbA1c
  • Baseline and follow-up cognitive assessment (MoCA/SLUMS)

Dosing and pricing for Cerebrolysin

Dosing references and compound pricing are available to established patients in the secure portal after a medical evaluation.

Ready to take control of your health?

Start with a 60-minute physician evaluation, virtually in seven states or in person in Reston, Virginia.

Request a consultation 703-400-5314

Cash-pay. HSA and FSA accepted. Monday–Friday, 10 AM – 2 PM (virtual and in person).